4.7 Article

A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's

Related references

Note: Only part of the references are listed.
Article Cardiac & Cardiovascular Systems

Age-related differences in the cutaneous vascular response to exogenous angiotensin II

James A. Lang et al.

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2019)

Article Peripheral Vascular Disease

Automated structure and flow measurement - a promising tool in nailfold capillaroscopy

Michael Berks et al.

MICROVASCULAR RESEARCH (2018)

Review Physiology

ANGIOTENSIN II SIGNAL TRANSDUCTION: AN UPDATE ON MECHANISMS OF PHYSIOLOGY AND PATHOPHYSIOLOGY

Steven J. Forrester et al.

PHYSIOLOGICAL REVIEWS (2018)

Review Rheumatology

Update of EULAR recommendations for the treatment of systemic sclerosis

Otylia Kowal-Bielecka et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

Article Pharmacology & Pharmacy

Angiotensin type 2 receptors: blood pressure regulation and end organ damage

Colin Sumners et al.

CURRENT OPINION IN PHARMACOLOGY (2015)

Review Rheumatology

The pathogenesis, diagnosis and treatment of Raynaud phenomenon

Ariane L. Herrick

NATURE REVIEWS RHEUMATOLOGY (2012)

Article Peripheral Vascular Disease

Coexistence of functional angiotensin II type 2 receptors mediating both vasoconstriction and vasodilation in humans

Francesca Schinzari et al.

JOURNAL OF HYPERTENSION (2011)

Article Peripheral Vascular Disease

Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients

Carmine Savoia et al.

HYPERTENSION (2007)

Article Dermatology

Human skin:: source of and target organ for angiotensin II

UM Steckelings et al.

EXPERIMENTAL DERMATOLOGY (2004)

Article Chemistry, Medicinal

Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist

YQ Wan et al.

JOURNAL OF MEDICINAL CHEMISTRY (2004)